FDA Drug Center Rotates Acting Deputy Director: Throckmorton Replaces Goldberger
This article was originally published in The Pink Sheet Daily
Executive Summary
Acting Center Deputy Director Goldberger will return to duties as director of Office of Drug Evaluation IV May 3, when Cardio-Renal Division Director Throckmorton will take his place. Acting Center Director Galson's letter to CDER staff indicates the center will remain without a permanent director for at least six to 12 months.